Why is Titan Biotech falling/rising?

As of 10-Jul, Titan Biotech Ltd's stock is currently priced at 455.00, reflecting a decrease of 1.0 (-0.22%). The stock has been underperforming recently, having fallen for the last two days with a total return decline of -0.66%. Despite outperforming its sector by 1.14% today, the stock's delivery volume has decreased significantly by -41.17% compared to the 5-day average, indicating a drop in investor participation. Over the past week, the stock has gained +4.80%, but it has a troubling year-to-date return of -37.91%, and it has underperformed the market over the last year with a return of -24.21%. The company's high management efficiency, indicated by a ROE of 25.08%, contrasts with its poor long-term growth metrics, including negative results for the last three consecutive quarters.
In the broader market context, while the Sensex has shown a slight decline of -0.06% over the past week, Titan Biotech's short-term performance has been more favorable, suggesting some resilience in the face of market pressures. However, the stock's significant underperformance over the past year, compared to the benchmark's return of +4.09%, highlights ongoing concerns about its valuation and growth prospects. The company's low debt-to-equity ratio is a positive factor, yet the expensive valuation, with a Price to Book Value of 2.5, raises questions about its sustainability in the current market environment. Overall, the combination of declining investor interest and disappointing financial results contributes to the stock's recent downward movement.